1496551-71-3

Basic information

• Product Name: ((2R,3R,4R,5R)-3-(benzoyloxy)-4-chloro-5-(2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)-4-Methyltetrahydrofuran-2-yl)Methyl benzoate
• Synonyms: ((2R,3R,4R,5R)-3-(benzoyloxy)-4-chloro-5-(2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)-4-Methyltetrahydrofuran-2-yl)Methyl benzoate;QUSIDKWVBPQGDG-PDKZGUECSA-N
• CAS NO: 1496551-71-3
• Molecular Formula: C₂₄H₂₁ClN₂O₇
• Molecular Weight: 484.88574
• Mol File: 1496551-71-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• PKA: 9.39±0.10(Predicted)
• CAS DataBase Reference: ((2R,3R,4R,5R)-3-(benzoyloxy)-4-chloro-5-(2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)-4-Methyltetrahydrofuran-2-yl)Methyl benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ((2R,3R,4R,5R)-3-(benzoyloxy)-4-chloro-5-(2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)-4-Methyltetrahydrofuran-2-yl)Methyl benzoate(1496551-71-3)
• EPA Substance Registry System: ((2R,3R,4R,5R)-3-(benzoyloxy)-4-chloro-5-(2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)-4-Methyltetrahydrofuran-2-yl)Methyl benzoate(1496551-71-3)

Safety Data

• Hazardous Substances Data: 1496551-71-3(Hazardous Substances Data)

Usage

General Description

The chemical compound "((2R,3R,4R,5R)-3-(benzoyloxy)-4-chloro-5-(2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)-4-Methyltetrahydrofuran-2-yl)Methyl benzoate" is a complex molecule with a combination of benzoyloxy, chloro, and methyl groups, as well as a tetrahydrofuran ring structure. It is a derivative of benzoic acid and contains a pyrimidine moiety. ((2R,3R,4R,5R)-3-(benzoyloxy)-4-chloro-5-(2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)-4-Methyltetrahydrofuran-2-yl)Methyl benzoate may have potential applications in pharmaceuticals and drug development, as well as in organic synthesis and chemical research. Its specific properties and potential uses would depend on further studies and investigations into its reactivity, stability, and biological activity.

Upstream product

• 1496551-70-2 2'-deoxy-2'-chloro-2'-C-methyl-3',5'-di-O-benzoyl-N⁴-benzoylcytidine 

Downstream Products

• 1496551-72-4 1-((2R,3R,4R,5R)-3-chloro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 1613590-78-5 C₁₇H₁₅ClFIN₂O₅ 
• 1613590-79-6 C₁₇H₁₆ClFN₂O₆ 
• 1613590-91-2 C₂₂H₂₈ClFN₃O₉P 
• 1496551-77-9 C₂₂H₂₉ClN₃O₉P 
• 1496551-77-9 (2R)-isopropyl 2-(((((2R,3R,4R,5R)-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate 

Relevant articles and documents

Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′- C-methyluridine 5′-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection

We report the synthesis and biological evaluation of a series of 4′-fluoro-2′-C-substituted uridines. Triphosphates of the uridine analogues exhibited a potent inhibition of hepatitis C virus (HCV) NS5B polymerase with IC50 values as low as 27 nM. In an HCV subgenomic replicon assay, the phosphoramidate prodrugs of these uridine analogues demonstrated a very potent activity with EC50 values as low as 20 nM. A lead compound AL-335 (53) demonstrated high levels of the nucleoside triphosphate in vitro in primary human hepatocytes and Huh-7 cells as well as in dog liver following a single oral dose. Compound 53 was selected for the clinical development where it showed promising results in phase 1 and 2 trials.

Deuterated HCV NS5b inhibitor nucleotide derivative and application thereof

The invention provides a deuterated HCV (Hepatitis C Virus) NS5b inhibitor nucleotide derivative or its pharmaceutically acceptable salts, stereoisomers, tautomer inhibitors and its application in preparation of drugs for treatment or prevention of HCV infection. The inhibitor is represented by a general formula I (shown in the description).

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.